Company / R&D Expense
Arcutis Biotherapeutics, Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$77.1M
FY2025
5-year range
$76.4M / $182.4M
FY2021-FY2025
Trend
+0.8%
vs FY2024
Sector context
#161 of 210
Health Care
What the data says
Arcutis Biotherapeutics, Inc.'s r&d expense of $77M is lower than 77% of companies in the Health Care sector (FY2025). R&D Expense returned to growth in FY2025 after 2 years of decline, reaching $77M.
Based on SEC 10-K filings.
$77M in FY2025 with a 5-year CAGR of -7.7%.
Declined from $111M to $77M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -25.0%
- 5-Year CAGR
- -7.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 210This company $77.1M Sector average $644.0M
▼
-88.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -7.7%, indicating a declining trend.
- In FY2025, r&d expense increased 0.8% year-over-year.
- Ranks #161 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.65 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $77.1M | +0.8% |
| FY2024 | $76.4M | -30.9% |
| FY2023 | $110.6M | -39.4% |
| FY2022 | $182.4M | +25.3% |
| FY2021 | $145.6M | +26.2% |
| FY2020 | $115.3M | +215.7% |
| FY2019 | $36.5M | +103.6% |
| FY2018 | $17.9M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026